Abstract
Background IgG4 is associated with two emerging groups of rare diseases: 1) IgG4 autoimmune diseases (IgG4-AID) and 2) IgG4-related diseases (IgG4-RLD). Anti-neuronal IgG4-AID include MuSK myasthenia gravis, LGI1- and Caspr2-encephalitis and autoimmune nodo-/paranodopathies (CNTN1 or NF155 antibodies). IgG4-RLD is a multiorgan disease hallmarked by tissue-destructive fibrotic lesions with lymphocyte and IgG4 plasma cell infiltrates and increased serum IgG4 concentrations. It is unclear, whether IgG4-AID and IgG4-RLD share relevant clinical and immunopathological features.
Methods We collected and analysed serological, clinical, and histopathological data in 50 patients with anti-neuronal IgG4-AID and 16 patients with IgG4-RLD.
Results A significantly higher proportion of IgG4-RLD patients had serum IgG4 elevation when compared to IgG4-AID patients (50% vs. 16%, p = .015). Moreover, those IgG4-AID patients with elevated IgG4 did not meet the diagnostic criteria of IgG4-RLD, and their autoantibody titres did not correlate with their serum IgG4 concentrations. In addition, patients with IgG4-RLD were negative for anti-neuronal/neuromuscular autoantibodies and among these patients, men showed a significantly higher propensity for IgG4 elevation, when compared to women (p = .041). Last, a kidney biopsy from a patient with autoimmune paranodopathy due to CNTN1/Caspr1-complex IgG4 autoantibodies and concomitant nephrotic syndrome did not show fibrosis or IgG4+ plasma cells, which are diagnostic hallmarks of IgG4-RLD.
Conclusion Our observations suggest that anti-neuronal IgG4-AID and IgG4-RLD are most likely distinct disease entities.
Competing Interest Statement
V. Endmayr reports no disclosures relevant to the manuscript. C. Tunc reports no disclosures relevant to the manuscript. L. Ergin reports no disclosures relevant to the manuscript. A. de Rosa reports no disclosures relevant to the manuscript. R. Weng reports no disclosures relevant to the manuscript. L. Wagner reports no disclosures relevant to the manuscript. T.Y. Yu reports no disclosures relevant to the manuscript. A. Fichtenbaum reports no disclosures relevant to the manuscript. T. Perkmann reports no disclosures relevant to the manuscript. H. Haslacher reports no disclosures relevant to the manuscript. N. Kozakowski reports no disclosures relevant to the manuscript. C. Schwaiger reports no disclosures relevant to the manuscript. G. Ricken reports no disclosures relevant to the manuscript. S. Hametner reports no disclosures relevant to the manuscript. L. Almeida Dutra received a grant from Fleury Laboratory for the Brazilian Autoimmune Encephalitis Project without personal compensation. C. Lechner served as a consultant for Roche. D. de Simoni reports no disclosures relevant to the manuscript. K.N. Poppert received a travel grant from Merck. G.J. Mueller reports no disclosures relevant to the manuscript. S. Pirker reports no disclosures relevant to the manuscript. W. Pirker reports no disclosures relevant to the manuscript. A. Angelovski reports no disclosures relevant to the manuscript. M. Valach reports no disclosures relevant to the manuscript. M. Maestri reports no disclosures relevant to the manuscript. M. Guida reports no disclosures relevant to the manuscript. R. Ricciardi reports no disclosures relevant to the manuscript. F. Frommlet reports no disclosures relevant to the manuscript. D. Sieghart reports no disclosures relevant to the manuscript. M. Pinter reports no disclosures relevant to the manuscript. R. Hoeftberger reports speakers honoraria from Novartis and Biogen. The Medical University of Vienna (Austria; employer of Dr. Hoeftberger) receives payment for antibody assays and for antibody validation experiments organized by Euroimmun (Luebeck, Germany). I. Koneczny reports no disclosures relevant to the manuscript.
Funding Statement
This work was supported by grants from the Austrian Science Fund (FWF), project number T996-B30, SYNABS project number I4685-B, DOC33-B27 and the Austrian Society of Neurology (Oesterreichische Gesellschaft fuer Neurologie). Figure 6 was created with BioRender software (license IK).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Institutional Review Boards of the Medical University of Vienna, Austria (EK 1442/2017).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
All authors have approved the final version of the manuscript.
Data Availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
